Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cipla
Mallinckrodt
McKinsey
Fish and Richardson
Teva
UBS
Argus Health
Johnson and Johnson
Baxter

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,703,787

« Back to Dashboard

Which drugs does patent 8,703,787 protect, and when does it expire?

Patent 8,703,787 protects ZYKADIA and is included in one NDA.

This patent has nineteen patent family members in nineteen countries.
Summary for Patent: 8,703,787
Title:Methods of using ALK inhibitors
Abstract: The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK.sup.+ mediated condition such as EML4-ALK.sup.+ non-small cell lung cancer, and optionally resistant to crizotinib; wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined above.
Inventor(s): Li; Nanxin (San Diego, CA), Harris; Jennifer Leslie (San Diego, CA), McNamara; Peter (San Diego, CA), Sun; Fangxian (Melrose, MA)
Assignee: IRM LLC (Hamilton, BM)
Application Number:13/981,046
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,703,787

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,703,787

PCT Information
PCT FiledFebruary 02, 2012PCT Application Number:PCT/US2012/023669
PCT Publication Date:August 09, 2012PCT Publication Number: WO2012/106540

International Patents Family Members for US Patent 8,703,787

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 20130121174 ➤ Subscribe
Japan 5837095 ➤ Subscribe
Japan 2014504646 ➤ Subscribe
Hungary E025395 ➤ Subscribe
Croatia P20150946 ➤ Subscribe
Spain 2543567 ➤ Subscribe
European Patent Office 2670401 ➤ Subscribe
Eurasian Patent Organization 023404 ➤ Subscribe
Eurasian Patent Organization 201391114 ➤ Subscribe
Denmark 2670401 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
McKinsey
Baxter
Moodys
Queensland Health
Argus Health
Merck
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot